UBS ធ្វើឱ្យប្រសើរឡើង Eli Lilly ប្រកាសថា LLY កំពុងធ្វើការលើ 'ថ្នាំធំបំផុតមិនធ្លាប់មាន'

UBS Group (SWX: UBSG), a global financial provider, បានធ្វើឱ្យប្រសើរ Eli Lilly (NYSE: LLY) to buy from neutral on Tuesday, September 20. UBS analyst Navin Jacob updated the price target from the previous $335 to the current, more កើនឡើង តម្លៃ ៩៩ ដុល្លារ។

The upgrade comes as Lilly starts submitting a marketing application for its medication “Donanemab”, a late-stage Alzheimer’s drug. The analyst called this drug “the biggest drug ever,” and the “highest potential late-stage Alzheimer’s asset”. 

“The key components of our buy thesis are, 1) Mounjaro (tirzepatide) – the SURMOUNT-1 readout was a best-in-class dataset with >20% weight loss and several underappreciated metrics (e.g. >95% of pre-diabetics normalized blood sugars) which should ultimately drive sales to our $25bn peak est.”

Jacob also added:

“Donanemab – while risky and not critical for the buy thesis, Donanemab is the highest potential late-stage Alzheimer’s asset, in our view, with LLY also being the best risk-reward play.”

តារាង LLY និងការវិភាគ 

Over the past month, LLY shares ជួញដូរ from $296.32 to $324.59, staying below មធ្យមការផ្លាស់ប្តូរ. The long-term trend is neutral, but the short-term trend remains negative, despite the positive upgrades. 

ការវិភាគបច្ចេកទេស បង្ហាញបន្ទាត់គាំទ្រនៅ $296.47 និង a តំបន់តស៊ូ ចាប់ពី ៧៥ ដុល្លារដល់ ១៥០ ដុល្លារ។ 

អ្នកវិភាគ TipRanks វាយតម្លៃភាគហ៊ុនថាជា 'ការទិញខ្លាំង' ជាមួយនឹងតម្លៃជាមធ្យមក្នុងរយៈពេល 12 ខែបន្ទាប់ឈានដល់ 368.63 ដុល្លារ។ ខ្ពស់ជាង 21.27% than the current trading price of $303.98. Notably, out of 9 market experts covering the stock, all gave LLY a buy rating. 

Currently, Eli Lilly shares are trading at roughly 32 times 2023 earnings consensus, giving them an appearance of a “pricey” stock; yet, UBS analysts’ decided to upgrade LLY, indicating that it deserves a high premium. 

Shareholders of the firm can be happy with the news as LLY is កើនឡើង 12.91% year-to-date (YTD), remaining a solid performer. Notably, back in June, ហ្វីនបុល said that Eli Lilly could be a recession-proof stock. On the other hand, investors looking to get in could sit on the sidelines to assess better entry positions if the markets take a turn for the worse. 

ទិញភាគហ៊ុនឥឡូវនេះជាមួយ Interactive Brokers ដែលជាវេទិកាវិនិយោគកម្រិតខ្ពស់បំផុត។

ការមិនទទួលខុសត្រូវ៖ ខ្លឹមសារនៅលើគេហទំព័រនេះមិនគួរត្រូវបានចាត់ទុកថាជាដំបូន្មានវិនិយោគទេ។ ការវិនិយោគគឺជាការប៉ាន់ស្មាន។ នៅពេលវិនិយោគ ដើមទុនរបស់អ្នកមានហានិភ័យ។